Value of perfusion thermo-chemotherapy combined with microspheres in the interventional treatment of primary liver cancer(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2018年第11期
- Page:
- 1339-1344
- Research Field:
- 医学生物物理
- Publishing date:
Info
- Title:
- Value of perfusion thermo-chemotherapy combined with microspheres in the interventional treatment of primary liver cancer
- Author(s):
- LIU Ya; ZENG Jianting; ZHANG Yanlin; LIANG Changyu; WANG Chunmei; ZHANG Bin
- Department of Medical Imaging, Chongqing Cancer Hospital, Chongqing University, Chongqing 400030, China
- Keywords:
- ; Keywords: primary liver cancer; perfusion thermo-chemotherapy; microspheres; interventional therapy
- PACS:
- R312；R735.7
- DOI:
- DOI:10.3969/j.issn.1005-202X.2018.11.019
- Abstract:
- Abstract: Objective To investigate the value of perfusion thermo-chemotherapy combined with microspheres in the transcatheter arterial chemoembolization (TACE) for primary liver cancer. Methods A total of 90 patients with primary liver cancer were selected and randomly divided into observation group and control group, with 45 cases in each group. The patients in observation group were treated with chemotherapy + lipiodol of 65° + microspheres sequential treatment combined with TACE, while those in control group were treated with chemotherapy + lipiodol at room temperature combined with emulsifier + microspheres sequential treatment combined with TACE. During the operation, two groups of patients received the chemotherapy with tegafur of 750 mg/m2 and oxaliplatin of 60 mg/m2 once every 4 weeks. A total of 2-6 cycles of chemotherapy were given. The short-term therapeutic effects were compared between two groups. Moreover, the changes of blood indexes before treatment and after 4 weeks of treatment were also compared. The blood indexes discussed in this research included alpha fetoprotein (AFP) and several liver and kidney function indexes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN), creatinine (CREA), albumin (ALB) and total bilirubin (TBIL). The incidence of toxic and adverse reactions and long-term follow-up results were also analyzed. Results The overall response rate was 84.44% in observation group and 64.44% in control group, with statistical differences (P<0.05). After 4 weeks of treatment, the AFP level in observation group was significantly lower than that before treatment (P<0.05), and no significant differences were found in the level of ALT, AST, BUN and CREA (P>0.05). In control group, there were no significant differences in above-mentioned indexes before and after treatment (P>0.05). After 4 weeks of treatment, no statistical significance was found in the indexes between two groups (P>0.05), except the AFP level which was significantly lower in observation group (P<0.05). The incidence of toxic and adverse reactions was 22.22% in observation group and 20.00% in control group, without statistical difference (P>0.05). The 2-year survival rate in observation group was significantly higher than that in control group (88.89% vs 71.11%, P<0.05). Conclusion Applying perfusion hyperthermic chemotherapy combined with microspheres for TACE in patients with primary liver cancer achieves remarkable short- and long-term therapeutic effects and has a low incidence of toxic and adverse reactions.
Last Update: 2018-11-22